Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Phreesia Inc (PHR) USD0.01

Sell:$58.99 Buy:$59.00 Change: $3.06 (4.93%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$58.99
Buy:$59.00
Change: $3.06 (4.93%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
Sell:$58.99
Buy:$59.00
Change: $3.06 (4.93%)
Market closed |  Prices as at close on 3 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Phreesia, Inc. is a United States-based healthcare software company. The Company provides healthcare organizations a suite of applications to manage the patient intake process and payment solution for patient payments. The Company provides software as a service platform which enables organizations to capture patient records and engage with patients. The Company’s software products enable appointments, registration, revenue cycle, patient surveys, patient activation, analytics and reports, and integration.

Contact details

Address:
434 FAYETTEVILLE ST., SUITE 1400
RALEIGH
27601
United States
Telephone:
+1 (646) 7479959
Website:
https://www.phreesia.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PHR
ISIN:
US71944F1066
Market cap:
$2.74 billion
Shares in issue:
44.16 million
Sector:
Health Care Technology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Weintraub
    Independent Chairman of the Board
  • Chaim Indig
    Chief Executive Officer, Director
  • Thomas Altier
    Chief Financial Officer
  • Evan Roberts
    Chief Operating Officer
  • Michael Davidoff
    Senior Vice President - Marketing and Business Development
  • Amy VanDuyn
    Senior Vice President - Human Resources
  • David Linetsky
    Senior Vice President - Life Sciences
  • Daniel Nathan
    Chief Technology Officer
  • Randy Rasmussen
    Chief Accounting Officer
  • Balaji Gandhi
    Vice President - Investor Relations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.